Notis McConarty Edward cut its position in Celgene Co. (NASDAQ:CELG) by 31.9% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 14,707 shares of the biopharmaceutical company’s stock after selling 6,900 shares during the period. Notis McConarty Edward’s holdings in Celgene were worth $1,359,000 as of its most recent SEC filing.
A number of other large investors have also recently added to or reduced their stakes in CELG. Archford Capital Strategies LLC lifted its position in shares of Celgene by 277.8% during the first quarter. Archford Capital Strategies LLC now owns 272 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 200 shares in the last quarter. Investors Research Corp acquired a new position in shares of Celgene during the first quarter worth approximately $28,000. Weaver Consulting Group acquired a new position in shares of Celgene during the first quarter worth approximately $29,000. Alera Investment Advisors LLC lifted its position in shares of Celgene by 109.9% during the first quarter. Alera Investment Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 167 shares in the last quarter. Finally, Mizuho Securities Co. Ltd. acquired a new position in shares of Celgene during the first quarter worth approximately $31,000. Hedge funds and other institutional investors own 74.77% of the company’s stock.
NASDAQ CELG traded down $1.03 during trading hours on Monday, hitting $92.84. The company’s stock had a trading volume of 248,536 shares, compared to its average volume of 3,875,716. The stock has a fifty day moving average of $93.40. Celgene Co. has a twelve month low of $58.59 and a twelve month high of $98.97. The firm has a market cap of $66.53 billion, a price-to-earnings ratio of 12.20, a P/E/G ratio of 0.44 and a beta of 1.46. The company has a quick ratio of 2.66, a current ratio of 3.44 and a debt-to-equity ratio of 1.97.
A number of equities analysts have recently issued reports on CELG shares. Mizuho reiterated a “buy” rating and set a $103.00 target price on shares of Celgene in a research report on Wednesday, July 3rd. Barclays lowered shares of Celgene from an “overweight” rating to an “equal weight” rating and set a $102.00 target price on the stock. in a research report on Friday, May 3rd. Cowen reiterated a “hold” rating and set a $102.00 target price on shares of Celgene in a research report on Tuesday, July 30th. Zacks Investment Research upgraded shares of Celgene from a “sell” rating to a “hold” rating and set a $94.00 target price on the stock in a research report on Tuesday, July 23rd. Finally, BidaskClub upgraded shares of Celgene from a “strong sell” rating to a “sell” rating in a research report on Saturday. Two research analysts have rated the stock with a sell rating, sixteen have issued a hold rating and four have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $94.81.
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.
See Also: What is systematic risk?
Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.